Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 26, 2017. The document serves as a formal notice to holders of the company's 5.375% Notes due 2034 (CUSIP # 377372 AB3) regarding administrative changes to the indenture governing these securities.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt levels, or liquidity metrics. This report is strictly administrative and does not contain financial performance data.
Material Changes
The material change disclosed is the resignation of Law Debenture Trust Company of New York as trustee, registrar, paying agent, and authenticating agent under the Indenture dated April 6, 2004 (as amended). Concurrently, Deutsche Bank Trust Company Americas has been appointed as the successor to these roles. These changes became effective at the opening of business on April 26, 2017.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is limited to the notification of the trustee change pursuant to Section 8.08 of the Indenture.
Key Facts for Investor Verification
- Successor Trustee: Deutsche Bank Trust Company Americas is now the trustee, registrar, paying agent, and authenticating agent.
- Effective Date: The change in trusteeship is effective as of April 26, 2017.
- Applicable Securities: This notice applies specifically to the 5.375% Notes due 2034.
- Contact Information: The designated corporate trust office for the successor trustee is located at 60 Wall Street, 16th Floor, New York, NY 10005.